文献速递消化内镜消化道肿瘤与早癌

非内镜筛查Barrett食管与食管腺癌在高危退伍军人中的应用

Nonendoscopic Screening for Barrett's Esophagus and Esophageal Adenocarcinoma in At-Risk Veterans.
PubMed 文献 · Am J Gastroenterol · 2024-07-11

本研究前瞻性评估EsoCheck/EsoGuard(EC/EG)非内镜筛查Barrett食管(BE)和食管腺癌(EAC)的诊断准确性、耐受性和可接受性。在符合ACG指南筛查标准的退伍军人中,124例完成EC/EG和食管胃十二指肠镜(EGD),BE/EAC患病率12.9%(16/124)。EC/EG灵敏度92.9%(95%CI 66.1-99.8),特异度72.2%(95%CI 62.1-80.8),阳性预测值32.5%(95%CI 18.6-49.1),阴性预测值98.6%(95%CI 92.4-100)。

要点

  • EC/EG对EGD检出的BE/EAC灵敏度为92.9%(95%CI 66.1-99.8),阴性预测值98.6%(95%CI 92.4-100)。
  • EC/EG特异度为72.2%(95%CI 62.1-80.8),阳性预测值为32.5%(95%CI 18.6-49.1)。
  • EC检查后平均可接受性评分为7.23(SD 2.45),基线焦虑评分反映围操作期明显焦虑。

核心结论

  • EC/EG在退伍军人筛查人群中显示出优异的灵敏度和阴性预测值,作者认为该 modality 是BE和EAC的有力筛查工具。

研究设计与样本

  • 前瞻性研究,在Louis Stokes Cleveland退伍军人事务医疗中心招募符合美国胃肠病学会(ACG)指南内镜筛查BE和EAC标准的退伍军人。
  • 所有参与者完成非镇静EC引导的远端食管取样,随后进行镇静食管胃十二指肠镜(EGD)。
  • 共782名合格退伍军人中130名(16.6%)接受食管癌筛查,最终分析完成两项筛查的124例。

主要发现

  • 基于EGD的BE/EAC患病率为12.9%(16/124)。
  • EC/EG对EGD检出BE/EAC的灵敏度为92.9%(95%CI 66.1-99.8),特异度为72.2%(95%CI 62.1-80.8)。
  • 阳性预测值为32.5%(95%CI 18.6-49.1),阴性预测值为98.6%(95%CI 92.4-100)。
  • 基线Spielberger状态-特质焦虑量表-6评分反映退伍军人在围操作期有明显焦虑水平。
  • EC检查后平均可接受性评分为7.23(SD 2.45)。

关键数值与推荐

  • 筛查人群符合美国胃肠病学会(ACG)指南内镜筛查BE和EAC的标准。
  • EC/EG灵敏度92.9%(95%CI 66.1-99.8),特异度72.2%(95%CI 62.1-80.8),阳性预测值32.5%(95%CI 18.6-49.1),阴性预测值98.6%(95%CI 92.4-100)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Although rates of esophageal adenocarcinoma (EAC) in the United States continue to rise, many patients at risk of disease are not screened. EsoCheck (EC), a nonendoscopic esophageal balloon sampling device coupled with EsoGuard (EG), a DNA-based screening assay, is an US Food and Drug Administration-approved minimally invasive alternative to the traditional screening method of upper endoscopy. The objective of this study was to prospectively determine the diagnostic accuracy, tolerance, and acceptability of the EC/EG test in a screening population. METHODS: We recruited veterans who met the American College of Gastroenterology Guideline criteria for endoscopic Barrett's esophagus (BE) and EAC screening at the Louis Stokes Cleveland Veterans Affairs Medical Center. All study participants completed unsedated EC-guided distal esophageal sampling followed by a sedated esophagogastroduodenoscopy (EGD). Diagnostic yield of the EG assay and EGD was recorded and used in calculation of sensitivity and specificity of EC/EG in prospective screening. The abbreviated Spielberger State-Trait Anxiety Inventory questionnaire was administered before and after completion of EC. Overall tolerance of EC sampling was evaluated on a 10-point Likert scale. RESULTS: Esophageal cancer screening was accepted by 130 of 782 eligible veterans (16.6%), and we analyzed results of those who completed both screening tests (N = 124). Prevalence of BE/EAC among studied veterans was 12.9% (16/124), based on EGD. Sensitivity and specificity of EC/EG for EGD-detected BE/EAC were 92.9% (95% confidence interval [CI] 66.1-99.8) and 72.2% (95% CI 62.1-80.8), respectively. Positive and negative predictive values were 32.5% (95% CI 18.6-49.1) and 98.6% (95% CI 92.4-100), respectively. Baseline Spielberger State-Trait Anxiety Inventory-6 scores were reflective of notable levels of anxiety among veterans in the periprocedural setting. The mean postprocedure acceptability score for the EC test was 7.23 (SD 2.45). DISCUSSION: Our data suggest excellent sensitivity and negative predictive value of EC/EG in a screening population of veterans, making this modality a powerful screening tool for BE and EAC.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Greer KB, Blum AE, Faulx AL, et al. Nonendoscopic Screening for Barrett's Esophagus and Esophageal Adenocarcinoma in At-Risk Veterans. Am J Gastroenterol. 2024. PMID: 38989889. doi:10.14309/ajg.0000000000002962

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。